Kestin v praktike otorinolaringologa


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The review has assessed the benefits of therapy with Kestine. Particular attention is paid to the use of drug for the treatment of perennial rhinitis. It is emphasized that Kestine suppresses not only early but also the late phase of allergic response. The results of the study of the EACCI working group are presented, indicating the proven efficacy of Kestine in acute respiratory infections. The evidence presented allow to conclude that the use of the drug Kestin reduces the need for co-administration of topical decongestants in allergic rhinitis which reduces the cost of therapy.

Texto integral

Acesso é fechado

Sobre autores

G. Tarasova

Email: gtarasova@yandex.ru

Bibliografia

  1. Белоусов Ю.Б., Лукьянова Е.М. Оценка эффективности и безопасности эбастина (кестина) при аллергических заболеваниях // Качественная клиническая практика 2002. № 1. С. 45-52.
  2. Секретарева Л.Б., Муратова Н.М. Кестин 20 мг - новая сила в терапии аллергического ринита // Росс. аллерголог. журн. 2008. № 2. С. 54-9.
  3. Татаурщикова Н.С. Кестин - от заслуженных успехов к новым инновационным достижениям // Фарматека 2013. № 1. С. 63-70.
  4. Benavente V, Eseverri JL, Botey J, Marin A. Ebastine: treatment of perennial rhinitis in the child. Allerg Immunol 1996;28(8):277-281.
  5. Gillen MS, Miller B, Chaikin P, Morrs G. J Effects of ebastine on ahroth the QT interval. Br J Clin Pharmacol 2001;52(2):201-04.
  6. Hurst M, Spencer CM. Ebastine - an update of its use in allergic disorders Drugs. 2000.59(4);981-006.
  7. RatnerPH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000;105(6 Pt 1):1101-107.
  8. Rohatagi S, Gillen M, Aubeneau M, Jan c, Pandi B, Jensen BK, Rhodes G. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther 2001;39(3):126-34.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies